Relacorilant (Lifyorli) added to nab-paclitaxel (Abraxane) produced a statistically significant overall survival improvement in the phase 3 ROSELLA trial for platinum-resistant ovarian cancer, with final data presented at the 2026 SGO Annual Meeting. Across 381 patients (188 in the combination arm vs 193 on nab-paclitaxel alone), the regimen cut the risk of death by 35% (HR 0.65; 95% CI 0.51–0.83; stratified log-rank P=0.0004). Median OS increased to 16.0 months from 11.9 months, with 12-month OS of 60% vs 50% and 18-month OS of 46% vs 27%. The OS benefit was consistent in prespecified subgroup analyses, including by prior therapy lines, prior PARP inhibitor exposure, and platinum-free interval length. The update also cites that the combination received FDA approval in March 2026 and is listed as a preferred option in NCCN guidelines for this setting. The reported results set up clinical and payer discussions around sequencing versus existing standard options for platinum-resistant disease, especially as combination regimens continue to move toward earlier lines.